Biocartis - Disclosure of a transparency notification

 

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that on 8 January 2018 it received a transparency notification dated 20 December 2017 (the 'Notification'), indicating that the shareholding of Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) has decreased below the 10% notification threshold. It concerns a passive downward crossing of the 10% notification threshold. As a result, Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) now holds 8.32% of the voting rights in Biocartis.

The Notification contains the following information:

 

  • Reason for the Notification: Acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer. Passive crossing of a threshold.

 

  • Notification by: A parent undertaking or a controlling person. 

 

  • Persons subject to the notification requirement: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.), Rue du Levant 146, 1920 Martigny, Switzerland; Debiopharm Holding S.A., Rue du Levant 146, 1920 Martigny, Switzerland; Thierry Mauvernay, Chemin du Praz-Buchilly 113, 1000 Lausanne 25, Switzerland.

 

  • Transaction date: 28 November 2017.

 

  • Threshold that is crossed: 10%.

 

  • Denominator: 51,069,772.

 

  • Details of the Notification: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.)  holds 4,249,707 voting rights.

 

  • Full chain of controlled undertakings through which the holding is effectively held: Debiopharm Innovation Fund S.A. (formerly Debiopharm Diagnostics S.A.) is controlled by Debiopharm Holding S.A., which is controlled by Thierry Mauvernay. 

 

  • Additional information: There was a transfer of controlling person and beneficial owner from Rolland-Yves Mauvernay to Thierry Mauvernay. 

 

The Notification is available here on the website of the Company.

 

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

Note

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers twelve oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?